Sartorius Stedim Biotech SA (DIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) has a cash flow conversion efficiency ratio of 0.044x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€182.60 Million ≈ $213.48 Million USD) by net assets (€4.14 Billion ≈ $4.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DIM equity to assets ratio to measure how much of total assets are equity-financed.
Sartorius Stedim Biotech SA - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DIM cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Sartorius Stedim Biotech SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sartorius Stedim Biotech SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carlyle Group Inc
NASDAQ:CG
|
0.064x |
|
VAT Group AG
SW:VACN
|
0.133x |
|
Taishin Financial Holding Co Ltd Pref
TW:2887E
|
-0.162x |
|
SCB X Public Company Limited
BK:SCB
|
0.025x |
|
Exor N.V.
AS:EXO
|
0.086x |
|
Emera Incorporated
NYSE:EMA
|
0.052x |
|
Bank of Ireland Group PLC
IR:BIRG
|
-0.021x |
|
Z HOLDINGS CORP. ADR 2
F:YOJ0
|
N/A |
Annual Cash Flow Conversion Efficiency for Sartorius Stedim Biotech SA (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sartorius Stedim Biotech SA from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see DIM market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €4.13 Billion ≈ $4.82 Billion |
€538.60 Million ≈ $629.68 Million |
0.131x | -35.56% |
| 2024-12-31 | €4.02 Billion ≈ $4.70 Billion |
€815.10 Million ≈ $952.94 Million |
0.203x | -27.45% |
| 2023-12-31 | €2.67 Billion ≈ $3.13 Billion |
€746.40 Million ≈ $872.62 Million |
0.279x | +14.65% |
| 2022-12-31 | €2.51 Billion ≈ $2.94 Billion |
€612.30 Million ≈ $715.84 Million |
0.244x | -39.35% |
| 2021-12-31 | €1.73 Billion ≈ $2.03 Billion |
€695.97 Million ≈ $813.66 Million |
0.402x | +42.84% |
| 2020-12-31 | €1.48 Billion ≈ $1.73 Billion |
€416.88 Million ≈ $487.38 Million |
0.281x | +6.75% |
| 2019-12-31 | €1.18 Billion ≈ $1.38 Billion |
€310.13 Million ≈ $362.57 Million |
0.263x | +21.07% |
| 2018-12-31 | €1.04 Billion ≈ $1.22 Billion |
€227.29 Million ≈ $265.72 Million |
0.218x | +9.51% |
| 2017-12-31 | €879.45 Million ≈ $1.03 Billion |
€174.69 Million ≈ $204.23 Million |
0.199x | -3.19% |
| 2016-12-31 | €763.56 Million ≈ $892.68 Million |
€156.66 Million ≈ $183.15 Million |
0.205x | -7.00% |
| 2015-12-31 | €647.22 Million ≈ $756.67 Million |
€142.79 Million ≈ $166.94 Million |
0.221x | +6.73% |
| 2014-12-31 | €538.51 Million ≈ $629.58 Million |
€111.31 Million ≈ $130.14 Million |
0.207x | +10.53% |
| 2013-12-31 | €481.84 Million ≈ $563.32 Million |
€90.11 Million ≈ $105.34 Million |
0.187x | +66.16% |
| 2012-12-31 | €434.72 Million ≈ $508.24 Million |
€48.93 Million ≈ $57.20 Million |
0.113x | -26.52% |
| 2011-12-31 | €395.63 Million ≈ $462.53 Million |
€60.59 Million ≈ $70.84 Million |
0.153x | -23.15% |
| 2010-12-31 | €365.07 Million ≈ $426.80 Million |
€72.76 Million ≈ $85.06 Million |
0.199x | -14.69% |
| 2009-12-31 | €393.20 Million ≈ $459.69 Million |
€91.86 Million ≈ $107.39 Million |
0.234x | +83.84% |
| 2008-12-31 | €371.65 Million ≈ $434.49 Million |
€47.23 Million ≈ $55.21 Million |
0.127x | +77.15% |
| 2007-12-31 | €362.76 Million ≈ $424.10 Million |
€26.02 Million ≈ $30.42 Million |
0.072x | -76.57% |
| 2006-12-31 | €168.93 Million ≈ $197.50 Million |
€51.72 Million ≈ $60.46 Million |
0.306x | +3.56% |
| 2005-12-31 | €148.35 Million ≈ $173.44 Million |
€43.85 Million ≈ $51.27 Million |
0.296x | -- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more